DD-723 Phase II clinical trial (Prostate)

DD-723 Phase II clinical trial - Dose-response study in patients with suspected prostate cancer -

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080220862

Enrollment

Registered

2009-09-15

Start date

2009-09-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with suspected prostate cancer

Interventions

investigational material(s) Generic name etc : DD-723 INN of investigational material : Perflubutane Therapeutic category code : 729 Other diagnostic agents (except extracorporeal diagnostic medicines

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: - Patients with suspected prostate cancer - Patients whose most recent PSA level is between 4.0 ng/mL and 20 ng/mL - Patients aged between 20 and 80 years at the time of informed consent

Exclusion criteria

Exclusion criteria: - Items listed on the package insert (including absolute contraindications, careful administration, and precautions) to ensure safety. - Items related to safety and ethics - Items related to surgery, procedures, and treatment that are considered to influence efficacy and safety assessment for this drug

Design outcomes

Primary

Measure	Time frame
Effectiveness of contrast effect	—

Secondary

Measure	Time frame
The detection rate of prostate cancer, and assessment of the degree of malignancy	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026